Trial Profile
A Prospective, Non-interventional, Registry Study of Patients Initiating a Course of DrugTherapy for Overactive Bladder (OAB)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Jun 2019
Price :
$35
*
At a glance
- Drugs Mirabegron (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Acronyms PERSPECTIVE
- Sponsors Astellas Pharma
- 20 Jun 2019 Results published in the Advances in Therapy
- 01 Jul 2018 Trial design published in the Contemporary Clinical Trials
- 17 Oct 2017 Status changed from active, no longer recruiting to completed.